As a result of the dynamic cooperation between FOXA1 and nuclear receptor function, loss of FOXA1 expression is sufficient to restrict ER and AR transcriptional activity, cell proliferation, and tumor growth in ER+ breast cancers and AR+ prostate cancers, respectively (13, 14). Here, FOXA1 is linked to prostate carcinoma.